QUEBEC CITY, Sept. 4 /CNW/ - Medicago Inc. (TSX-V : MDG) (the "Company"),
today announced that it has granted 140,505 stock options to Andy Sheldon,
President and Chief Executive Officer and 83,169 to Louis P. Vézina, Chief
Scientific Officer, pursuant to the terms of their employment agreements and
conditions of the Company's stock option plan. These stock options were issued
at an exercise price of $0.37 and expire in five years.
About Medicago Inc.
Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.
The TSX Venture Exchange assumes no responsibility for the content or
accuracy of this press release
For further information:
For further information: Medicago Inc., Andy Sheldon, President and CEO;
Pierre Labbé, Vice president and CFO, (418) 658-9393